271 related articles for article (PubMed ID: 17992493)
41. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
Gasser P; Tarchevskaya SS; Guntern P; Brigger D; Ruppli R; Zbären N; Kleinboelting S; Heusser C; Jardetzky TS; Eggel A
Nat Commun; 2020 Jan; 11(1):165. PubMed ID: 31913280
[TBL] [Abstract][Full Text] [Related]
42. Omalizumab: not only for asthma.
Ben-Shoshan M
Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009
[TBL] [Abstract][Full Text] [Related]
43. Effects of omalizumab in patients with food allergy.
Rafi A; Do LT; Katz R; Sheinkopf LE; Simons CW; Klaustermeyer W
Allergy Asthma Proc; 2010; 31(1):76-83. PubMed ID: 20167148
[TBL] [Abstract][Full Text] [Related]
44. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
45. Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody.
Berger WE
Allergy Asthma Proc; 2006; 27(2 Suppl 1):S29-32. PubMed ID: 16722329
[TBL] [Abstract][Full Text] [Related]
46. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
[TBL] [Abstract][Full Text] [Related]
47. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Nayak A; Casale T; Miller SD; Condemi J; McAlary M; Fowler-Taylor A; Della Cioppa G; Gupta N
Allergy Asthma Proc; 2003; 24(5):323-9. PubMed ID: 14619332
[TBL] [Abstract][Full Text] [Related]
48. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
[TBL] [Abstract][Full Text] [Related]
49. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
D'Amato G
Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
[TBL] [Abstract][Full Text] [Related]
50. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
Kupryś-Lipińska I; Kuna P
Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
[TBL] [Abstract][Full Text] [Related]
51. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
[TBL] [Abstract][Full Text] [Related]
52. Omalizumab: efficacy in allergic disease.
Spector S
Panminerva Med; 2004 Jun; 46(2):141-8. PubMed ID: 15507883
[TBL] [Abstract][Full Text] [Related]
53. Targeting immunoglobulin E as a novel treatment for asthma.
Sandström T
Curr Allergy Asthma Rep; 2005 Mar; 5(2):109-15. PubMed ID: 15683610
[TBL] [Abstract][Full Text] [Related]
54. From allergy to anti-IgE: targeting the cause.
Oldani V
Monaldi Arch Chest Dis; 2002 Apr; 57(2):115-6. PubMed ID: 12357839
[TBL] [Abstract][Full Text] [Related]
55. Omalizumab.
Easthope S; Jarvis B
Drugs; 2001; 61(2):253-60; discussion 261. PubMed ID: 11270941
[TBL] [Abstract][Full Text] [Related]
56. Treating atopic asthma with the anti-IgE monoclonal antibody.
D'Amato G
Monaldi Arch Chest Dis; 2002 Apr; 57(2):117-9. PubMed ID: 12357840
[TBL] [Abstract][Full Text] [Related]
57. Omalizumab in asthma: approval and postapproval experience.
Chiang DT; Clark J; Casale TB
Clin Rev Allergy Immunol; 2005 Aug; 29(1):3-16. PubMed ID: 16222080
[TBL] [Abstract][Full Text] [Related]
58. Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persistent allergic asthma patients with diabetes mellitus: 18 month follow-up.
Yalcin AD; Gorczynski RM; Cilli A; Strauss L
Clin Lab; 2014; 60(9):1561-4. PubMed ID: 25291953
[TBL] [Abstract][Full Text] [Related]
59. Mechanisms of action of anti-immunoglobulin E therapy.
Soresi S; Togias A
Allergy Asthma Proc; 2006; 27(2 Suppl 1):S15-23. PubMed ID: 16722327
[TBL] [Abstract][Full Text] [Related]
60. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
